Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration has cleared the Company's Investigational New Drug application for ORMD-0801, its oral insulin capsule. "We are very pleased to have the FDA clearance to proceed," stated Nadav Kidron, CEO of Oramed. Oramed...
pSivida Corp., a company focused on developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced financial results for its third quarter ended March 31. "We are very pleased that the FDA has accepted Alimera Sciences' recently resubmitted New Drug Application for ILUVIEN for chronic Diabetic Macular Ede
Dublin- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Cardiovascular Drug Delivery- Technologies, Markets and Companies" to their offering. Drug delivery to the cardiovascular system is different from delivery to other systems because of the anatomy and physiology of the vascular system; it supplies blood and..
Research and Markets has announced the addition of Jain PharmaBiotech's new report "Cardiovascular Drug Delivery- Technologies, Markets and Companies" to their offering. Drug delivery to the cardiovascular system is different from delivery to other systems because of the anatomy and physiology of the vascular system; it supplies blood and nutrients
By a News Reporter-Staff News Editor at Journal of Engineering Research and Markets has announced the addition of the "Drug Delivery: Surveying the Global Competitive Landscape" report to their offering. Drug Delivery: Surveying the global competitive landscape is a richly-detailed report which examines, in depth, 106 leading and emerging special
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces that it has engaged Plexus Ventures, a leading strategic advisor to the pharmaceutical, biotechnology and drug delivery industries worldwide, to explore options for DSC127 outside the U.S. "Plexus Ventures is a premier strategic advisory fir
By a News Reporter-Staff News Editor at Journal of Technology Research and Markets has announced the addition of the "Drug Delivery: Surveying the Global Competitive Landscape" report to their offering. Drug Delivery: Surveying the global competitive landscape is a richly-detailed report which examines, in depth, 106 leading and emerging speciali
Tris Pharma, a specialty pharmaceutical company focused on developing drug delivery technologies, announced that Ketan Mehta, the company's Founder, President and Chief Executive Officer, has been named a finalist for the Ernst and Young Entrepreneur of the Year 2013 Award in the New Jersey region. "I'm thrilled to be a finalist for the Ernst and
pSivida Corp., a developer of sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced that the U.S. Food and Drug Administration acknowledged receipt of the resubmission of the New Drug Application for ILUVIEN for treatment of chronic diabetic macular edema and stated that the resubmission was considered a...
Release date- 13052013- LONDON, UK- Skyepharma PLC, the expert oral and inhalation drug delivery company announces that the United States Food and Drug Administration has approved the New Drug Application for BREO ELLIPTA, a combination product submitted by GlaxoSmithKline for the long-term, once-daily, maintenance treatment of airflow obstruction
Led by needle-free delivery systems, the advanced implantable/injectible drug delivery market reached revenues of $13.3 billion in 2012, according to their recently published report The World Market for Injectable, Implantable and Needle-Free Drug Delivery Systems. In 2017, the implantable/injectable drug delivery market, is expected to reach...
By a News Reporter-Staff News Editor at Diabetes Week pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced that the U.S. Food and Drug Administration acknowledged receipt of the resubmission of the New Drug Application for ILUVIEN for treatment of chronic diabetic
pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its third quarter ended March 31, 2013. We are very pleased that the FDA has accepted Alimera Sciences recently resubmitted New Drug Application for ILUVIEN for chronic Diabetic Ma
Research and Markets has announced the addition of the "Injectable Drug Delivery Market by Formulations, Devices& Therapeutics- Global Forecasts to 2017" report to its offerings. In a release, Research and Markets noted that report highlights include:. The global injectable drug delivery technologies market was valued at $22.5 billion in 2012, and
Tris has achieved significant growth since Mr. Mehta founded the company in 2000. Under his leadership, Tris has developed multiple proprietary drug delivery technologies that fulfill an unmet need among people who have difficulty swallowing pills. Tris has launched several important products and continues to partner with key pharmaceutical compani
By a News Reporter-Staff News Editor at Gene Therapy Weekly Data detailed on Drug Development have been presented. According to news reporting originating in Baltimore, Maryland, by NewsRx journalists, research stated, "Intravitreal injection of biodegradable nanoparticles holds promise for gene therapy and drug delivery to the back of the eye.
Dublin- Research and Markets has announced the addition of the "Injectable Drug Delivery Market by Formulations, Devices& Therapeutics- Global Forecasts to 2017" report to their offering. The global injectable drug delivery technologies market was valued at $22.5 billion in 2012, and is expected to reach $43.3 billion by 2017 at a CAGR of 14.0% fro
Research and Markets has announced the addition of the "Injectable Drug Delivery Market by Formulations, Devices& Therapeutics- Global Forecasts to 2017" report to their offering. The global injectable drug delivery technologies market was valued at $22.5 billion in 2012, and is expected to reach $43.3 billion by 2017 at a CAGR of 14.0% from 2012 t
Tris Pharma, a specialty pharmaceutical company focused on developing drug delivery technologies, announced that Ketan Mehta, the company's Founder, President and Chief Executive Officer, has been named a finalist for the Ernst and Young Entrepreneur of the Year 2013 Award in the New Jersey region. "I'm thrilled to be a finalist for the Ernst and
NESS ZIONA, Israel, May 6, 2013/ PRNewswire/. Mapi Pharma Ltd., developer of complex bulk Active Pharmaceutical Ingredients, generic and innovative intermediates, and finished dosage forms based on selected drug delivery systems, announced today that the company has been granted a United States patent for a long acting depot formulation of glatir
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by the inventors Smith, Christopher James, filed on February 15, 2011, was made available online on April 25, 2013. The assignee for this patent application, patent application ser
pSivida Corp., a developer of sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced that the U.S. Food and Drug Administration acknowledged receipt of the resubmission of the New Drug Application for ILUVIEN for treatment of chronic diabetic macular edema and stated that the resubmission was considered a...
SAN FRANCISCO, May 3, 2013 MRI Interventions, Inc. today announced that its ClearPoint Neuro Intervention System will be highlighted as a platform for MRI-guided drug delivery to the brain at the 2013 Annual Targeted Drug Delivery Conference in San Francisco in three presentations to be given during the session "Amazing Things on the Horizon f
Pharmaco-Kinesis Corp., a medical device company developing smart implantable pumps and medications for local drug delivery, has reported development of the first combinatorial nano-drug product candidate, a combination of Temozolomide and Thalidomide nanoparticles to be tested for treatment of gliomas and other cancers. Based on the collaboration.
Dublin- Research and Markets has announced the addition of the "Hungary Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2018" report to their offering. Hungary Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2018, a new report by Global Markets Direct, provides key market data on the Ireland Drug
